In 2003, the approval of gefitinib by the Food and Drug Administration (FDA), as the first molecular targeted drug for NSCLC treatment, led the way for the development of potent inhibitors such as EGFR, ALK, RET, and KRAS (3, 4). Here, ALK is linked to non-small cell lung carcinoma.